Frost & Sullivan Honours ALRISE for Resolving Key Unmet Needs in Drug Delivery
2014-09-06 / Based on Frost & Sullivan’s recent analysis of the European drug delivery landscape, ALRISE Biosystems GmbH was recognised as winner of the 2014 Frost & Sullivan Technology Innovation Leadership Award.
“ALRISE’s depot formulations are characterised in particular by enabling low initial burst, high encapsulation efficiency, high reproducibility, and preservation of protein drug biological activity,” said Frost & Sullivan Research Analyst Srinivas Sashidhar. “These are just some of the reasons why we believe that the innovative ImSus® technology platform has the potential to make the drug development process more efficient and simple.”
“Best Practices Examples” according to the Frost & Sullivan Report are these: ImSus® stands out by using exclusively non-harmful (non-carcinogenic) organic solvents classified as Class III according to ICH guidelines. In addition, any other excipients used are generally considered as safe (GRAS), according to FDA. The in-vivo release performance of ALRISE’s depot forms is adapted to the target product profile by varying microparticle formulation as well as size distribution and morphology.
ALRISE’s CEO Celal Albayrak stated, "We are truly honoured to be recognized by Frost & Sullivan, who is a global industry leader in analysing markets, industry trends and best practices. This Best Practices Award is a great testament to our proven technology success and supports how our work ultimately drives value for our customers. This recognition further validates our market reputation and our focus on our customers."
ALRISE is committed to deliver solutions optimising product life cycle management as well as enhancing performance of its partners' drugs in development. Moreover, ALRISE reformulates off-patent drugs to develop supergeneric products both alone and in cooperation with generics companies. ALRISE has formulation development capabilities for a scale that enables batch sizes up to 500 g of freeze-dried micro particles, which is sufficient for the supply of Phase I / Phase II clinical trials. Further scale-up to commercial batch sizes is carried out by a contract manufacturer with technical support from ALRISE.
Source: Press Release Alrise